Pediatric Access To Unapproved Drugs Is Next Topic For Oncology Subcmte
Executive Summary
Pediatric use of unapproved cancer drugs will be the next topic on the table for FDA's Pediatric Subcommittee of the Oncologic Drugs Advisory Committee
You may also be interested in...
Pediatric Oncology Labeling Should Reflect Exploratory Approach – Pazdur
Oncologic drug pediatric labeling should reflect the exploratory nature of the field, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, said during an advisory committee meeting March 4
Pediatric Oncology Labeling Should Reflect Exploratory Approach – Pazdur
Oncologic drug pediatric labeling should reflect the exploratory nature of the field, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, said during an advisory committee meeting March 4
FDA Role In Prioritizing Pediatric Oncologic Development On Cmte. Agenda
FDA's Pediatric Oncology Subcommittee should consider whether the agency should contribute to the prioritization of development of pediatric oncologic therapies, participants in FDA's workshop on pediatric oncology drug development agreed